Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17217979 | 0.98 | DNM1 (0.32) | DNM1LMNATHRBHTTSPHK1 | |
| SCHEMBL17219052 | 0.91 | ADRB2 (0.33) | THRBTSHR | |
| SCHEMBL17218866 | 0.82 | — | — | |
| SCHEMBL28155120 | 0.78 | TSHR (0.40) | DNM1THRBHTTTSHRMEN1 | |
| SCHEMBL16760861 | 0.78 | TSHR (0.40) | DNM1THRBHTTTSHRMEN1 | |
| SCHEMBL5958124 | 0.76 | THRB (0.38) | THRBHTTTSHRMEN1KMT2A | |
| SCHEMBL16760855 | 0.75 | LPAR1 (0.35) | THRBHTTTSHRMEN1KMT2A | |
| SCHEMBL6958693 | 0.75 | CHRM2 (0.33) | TSHRMEN1KMT2A | |
| SCHEMBL17216773 | 0.74 | THRB (0.40) | THRBHTTTSHRUSP2MEN1 | |
| SCHEMBL6571639 | 0.74 | TSHR (0.36) | THRBHTTTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2940012-B1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL CO (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-9560850-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20150336908-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
| EP-2940012-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | Sumitomo Chemical Company Limited (JP) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336908-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | RTN3, CYP51A1, TCOF1 | DNM1 2625/4885LMNA 2406/4885THRB 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.